Dow Today: Goldman Sachs Group (GS) Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Dow Jones Industrial Average ( ^DJI) is trading up 53 points (+0.3%) at 16,232 as of Wednesday, Feb 26, 2014, 1:35 p.m. ET. During this time, 256.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 394.3 million. The NYSE advances/declines ratio sits at 2,037 issues advancing vs. 915 declining with 163 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Holding back the Dow today is Goldman Sachs Group (NYSE: GS), which is lagging the broader Dow index with a 41-cent decline (-0.3%) bringing the stock to $162.52. Volume for Goldman Sachs Group currently sits at 2.6 million shares traded vs. an average daily trading volume of 3.1 million shares.

Goldman Sachs Group has a market cap of $75.48 billion and is part of the financial sector and financial services industry. Shares are down 7.8% year to date as of Tuesday's close. The stock's dividend yield sits at 1.3%.

The Goldman Sachs Group, Inc. provides investment banking, securities, and investment management services, as well as financial services to corporations, financial institutions, governments, and high-net-worth individuals worldwide.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing